Keywords: symbicort, approved, usa, copd, anglo-swedish, drug, major
Symbicort approved in USA for COPD
Article | 09 March 2009
Anglo-Swedish drug major AstraZeneca's Symbicort (budesonide/formoterol fumarate dihydrate) 160mcg/4.5mcg has been approved in the USA for the twice-daily ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
